Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» BMS-791325
BMS-791325
3 Companies Racing to Transform Hepatitis-C Treatment
3 Companies Racing to Transform Hepatitis-C Treatment
Motley Fool
hepatitis C
Gilead
sofosbuvir
AbbVie
Bristol-Myers Squibb
daclatasvir
asunaprevir
BMS-791325
Flag link:
Three Future Winners and One Major Loser in the HCV Wars
Three Future Winners and One Major Loser in the HCV Wars
Motley Fool
hepatitis C
AbbVie
Bristol-Myers Squibb
Gilead
Idenix
sofosbuvir
ledipasvir
daclatasvir
asunaprevir
BMS-791325
IDX20963
Flag link:
Bristol Still Playing Catch-Up To Gilead In Hep C Drug Race
Bristol Still Playing Catch-Up To Gilead In Hep C Drug Race
TheStreet.com
Gilead
Bristol-Myers Squibb
hepatitis C
sofosbuvir
daclatasvir
asunaprevir
BMS-791325
Flag link:
Bristol-Myers Hepatitis C Combo Therapy Blunts Disease
Bristol-Myers Hepatitis C Combo Therapy Blunts Disease
Bloomberg
BMS-791325
Bristol-Myers Squibb
hepatitis C
daclatasvir
asunaprevir
Flag link:
Bristol-Myers Hepatitis C Combo Therapy Shows Promise
Bristol-Myers Hepatitis C Combo Therapy Shows Promise
Bloomberg
hepatitis C
Bristol-Myers Squibb
BMS-791325
asunaprevir
declatasvir
Flag link:
